PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here’s How Posted byZacks Equity Research September 20, 2021 Leave a comment on PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here’s How PerkinElmer’s (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.